| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03233217 | Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years | PHASE1 | COMPLETED | 175 | — | — | Sep 15, 2017 | Nov 28, 2017 | Apr 4, 2022 | 2 | Japan |
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of symptom and/or onset post-vaccination. Unsolicited AEs includes both serious and non-serious unsolicited AEs. A serious adverse event is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.
A solicited reaction was an adverse reaction observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited injection site reactions: pain, erythema, swelling, induration, and bruising. Solicited systemic reactions: fever, headache, malaise, myalgia, and shivering.
An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of symptom and/or onset post-vaccination. Unsolicited AEs included both serious and non-serious unsolicited AEs. A serious adverse event is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: QIV-HD by IM | EXPERIMENTAL | Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0. |
| Cohort 1: QIV-HD by SC | EXPERIMENTAL | Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0. |
| Cohort 2: QIV-HD by IM | EXPERIMENTAL | Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0. |
| Cohort 2: QIV-HD by SC | EXPERIMENTAL | Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0. |
| Cohort 2: QIV-SD by SC | ACTIVE_COMPARATOR | Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0. |
| Name | Type | Description |
|---|---|---|
| QIV-HD by IM | BIOLOGICAL | IM, injected into the upper arm (deltoid area) |
| QIV-SD by SC | BIOLOGICAL | SC, injected into the upper arm (posterior region) |
| QIV-HD by SC | BIOLOGICAL | SC, injection into the upper arm (posterior region) |
Inclusion Criteria: * Aged \>= 65 years on the day of inclusion. * Informed consent form has been signed and dated. * Able to attend all scheduled visits and to comply with all study procedures. Exclusion Criteria: * Participation at the time of study enrollment (or in the 4 weeks preceding the s...